FLX Bio to Present at Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference

November 27, 2017

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--FLX Bio, Inc., a biopharmaceutical company focused on the discovery and development of oral small-molecule drugs to activate the immune system, today announced that Brian Wong, M.D., Ph.D., CEO and Rekha Hemrajani, COO will participate in an analyst-led fireside chat at the Evercore ISI Biopharma Catalyst/Deep Dive Conference on November 29, 2017 at 1:15 p.m. ET in Boston, Mass, as well as investor meetings.

About FLX Bio

FLX Bio, Inc. is a cancer immunotherapy company focused on the discovery and development of orally-available, small molecule drugs to activate the immune system and eradicate cancer. Using its integrated immuno-oncology drug discovery platform, FLX Bio’s small molecule compounds specifically target proteins and pathways that selectively inhibit regulatory T cells and myeloid cells within the tumor microenvironment. Its lead candidate FLX475, a best-in-class CCR4 inhibitor, has the potential to be used alone or in combination with checkpoint inhibitors to treat a variety of cancers, and is expected to enter the clinic in 2017.

Located in South San Francisco, Calif., and funded by leading investors, including Kleiner Perkins Caufield & Byers (KPCB), The Column Group (TCG), Topspin Partners and Celgene, FLX Bio has assembled a leadership team and advisory group with a proven track record of success and team of scientists with substantial knowledge and expertise in drug discovery and translational areas essential to execute on this approach. For more information, please visit www.flxbio.com.



For FLX Bio, Inc.
Angela Bitting, 925-202-6211

« back to news page